I think we're holding back a little to have a call next week, and word of that should be coming up. I guess I'm a little surprised- and somewhat concerned that we didn't get interim data on the most recent cancer patients. This isn't going to work for everybody, that's just the way things work in medicine. Based on recent releases, the price didn't move much anyway. We need validation from outside to move the needle much.